Advances in the systemic therapy of malignant pleural mesothelioma
Fennell, D. A., Gaudino, G., O'Byrne, Kenneth J., Mutti, L., & van Meerbeeck, J. (2008) Advances in the systemic therapy of malignant pleural mesothelioma. Nature Clinical Practice Cardiovascular Medicine, 5(3), pp. 136-147.
Malignant pleural mesothelioma is an aggressive thoracic malignancy associated with exposure to asbestos, and its incidence is anticipated to increase during the first half of this century. Chemotherapy is the mainstay of treatment, yet sufficiently robust evidence to substantiate the current standard of care has emerged only in the past 5 years. This Review summarizes the evidence supporting the clinical activity of chemotherapy, discusses the use of end points for its assessment and examines the influence of clinical and biochemical prognostic factors on the natural history of malignant pleural mesothelioma. Early-phase clinical trials of second-line and novel agents are emerging from an increased understanding of mesothelioma cell biology. Coupled with high-quality translational research, such developments have real potential to improve the outlook of patients at a time of increasing incidence.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||Biomarkers, Chemotherapy, Mesothelioma, Novel therapy, Pleural, 3 phenylsulfamoylcinnamohydroxamic acid, 5 aza 2' deoxycytidine, alkylating agent, anthracycline, antineoplastic antimetabolite, asbestos, bevacizumab, carboplatin, cediranib, cisplatin, depsipeptide, DNA topoisomerase inhibitor, doxorubicin, flavopiridol, gemcitabine, histone deacetylase inhibitor, imatinib, mitomycin, mitoxantrone, navelbine, pemetrexed, platinum derivative, raltitrexed, sorafenib, sunitinib, taxane derivative, unindexed drug, vinblastine, Vinca alkaloid, vorinostat, anthracycline derivative, antineoplastic agent, fluorodeoxyglucose f 18, folic acid antagonist, placebo, proteome, vindesine, cancer chemotherapy, cancer incidence, cancer research, clinical trial, combination chemotherapy, disease course, drug design, drug fatality, human, malignant mesothelioma, monotherapy, patient care, pleura mesothelioma, priority journal, prognosis, review, systemic therapy, thorax cancer, biochemistry, cancer cell, cancer staging, cancer survival, computer assisted emission tomography, cytology, disease free survival, drug choice, drug efficacy, drug mechanism, drug response, drug safety, dyspnea, glioblastoma, lung surgery, multiple cycle treatment, overall survival, pain, protein targeting, survival rate, survival time, therapy delay, treatment duration, treatment planning, Antineoplastic Agents, Combined Modality Therapy, Folic Acid Antagonists, Gene Expression Profiling, Humans, Platinum Compounds, Pleural Neoplasms, Positron-Emission Tomography, Treatment Outcome, Tumor Markers, Biological|
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2008 Nature Publishing Group|
|Deposited On:||03 Dec 2013 07:12|
|Last Modified:||11 Mar 2014 06:04|
Repository Staff Only: item control page